+420.3%
NVT vs GSK
+47.2%
+373.1%
-46.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.6% | 0.0% | +4.6% | +4.6% |
| 7D | +4.1% | -3.5% | +7.6% | +4.5% |
| 30D | -5.1% | -3.4% | -1.7% | -4.9% |
| 3M | -1.2% | -8.1% | +7.0% | -0.4% |
| 6M | +46.6% | -11.1% | +57.7% | +48.6% |
| YTD | +60.0% | +0.7% | +59.2% | +58.3% |
| 1Y | +70.8% | +20.1% | +50.7% | +63.1% |
| 3Y | +187.5% | +46.1% | +141.4% | +155.6% |
| All | +420.3% | +47.2% | +373.1% | +318.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling